酒精戒断症状对哌唑嗪疗效的调节作用
一项12周双盲随机对照概念验证试验在100例酒精依赖成人中检验哌唑嗪(16 mg/日)疗效是否受酒精戒断症状调节。高戒断症状者使用哌唑嗪后重度饮酒天数和饮酒天数显著低于安慰剂组,低或无戒断症状者未见此获益。哌唑嗪还改善高戒断症状者的焦虑、抑郁和酒精渴求。
要点
- 酒精戒断症状可调节哌唑嗪对饮酒结局的疗效。
- 高戒断症状者哌唑嗪组第12周重度饮酒天数7.07%、饮酒天数27.46%。
- 低或无戒断症状者未观察到哌唑嗪的饮酒获益。
核心结论
- 酒精戒断症状是哌唑嗪治疗酒精使用结局及相关症状的显著调节因素。
研究设计与样本
- 12周双盲随机对照概念验证试验,社区招募当前酒精依赖成人100例,哌唑嗪16 mg/日(2周滴定)。
主要发现
- 戒断症状评分×治疗×全剂量治疗期(第3-12周)对饮酒天数、重度饮酒天数和日均饮酒量存在显著交互作用。
- 第12周高戒断症状者中,哌唑嗪组重度饮酒天数7.07%、饮酒天数27.46%,安慰剂组分别为35.58%和58.47%。
- 高戒断症状者重度饮酒天数比值比0.14(95% CI=0.058, 0.333),饮酒天数比值比0.265(95% CI=0.146, 0.481)。
- 高戒断症状者哌唑嗪组较安慰剂组焦虑、抑郁和酒精渴求显著改善。
- 低或无戒断症状者未观察到此获益。
关键数值与推荐
- 高戒断症状者哌唑嗪组第12周重度饮酒天数7.07%、饮酒天数27.46%,安慰剂组35.58%和58.47%。
- 重度饮酒天数比值比0.14(95% CI=0.058, 0.333),饮酒天数比值比0.265(95% CI=0.146, 0.481)。
临床怎么用
- 酒精戒断症状可能作为哌唑嗪治疗酒精使用障碍疗效的预后指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Alcohol use disorder (AUD) is a leading cause of global disease burden. Chronic, heavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of alcohol craving and mood, anxiety, and sleep disturbances, which are predictive of poor treatment outcomes. The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in reducing alcohol intake and associated secondary outcomes. METHODS: A 12-week, double-blind, randomized, controlled proof-of-concept trial of prazosin (16 mg/day, with a 2-week titration) was conducted in community-recruited adults with current alcohol dependence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry. Primary outcomes were daily self-reported drinking days and heavy drinking days, and secondary outcomes were average drinks/day and mood, anxiety, craving, and sleep quality ratings. RESULTS: Modified intent-to-treat analyses indicated a significant interaction of alcohol withdrawal symptom score by treatment by full-dose treatment period (weeks 3-12) for drinking days, heavy drinking days, and average drinks/day. By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% heavy drinking days and 27.46% drinking days, while those on placebo had 35.58% heavy drinking days and 58.47% drinking days (heavy drinking days: odds ratio=0.14, 95% CI=0.058, 0.333; drinking days: odds ratio=0.265, 95% CI=0.146, 0.481). No such benefit of prazosin was observed in those reporting low or no alcohol withdrawal symptoms. Individuals with high alcohol withdrawal symptoms on prazosin compared with placebo also showed significantly improved anxiety, depression, and alcohol craving over the course of the trial. CONCLUSIONS: The findings indicate that alcohol withdrawal symptoms are a significant moderator of prazosin treatment response for alcohol use outcomes and for associated symptoms of alcohol craving, anxiety, and mood symptoms. These data support further evaluation of alcohol withdrawal symptoms as a prognostic indicator of prazosin's efficacy in the treatment of AUD.
引用
- Sinha R, Wemm S, Fogelman N, et al. Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms. Am J Psychiatry. 2020. PMID: 33207935. doi:10.1176/appi.ajp.2020.20050609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。